BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 19528235)

  • 1. Increased c-Jun expression and reduced GATA2 expression promote aberrant monocytic differentiation induced by activating PTPN11 mutants.
    Yang Z; Kondo T; Voorhorst CS; Nabinger SC; Ndong L; Yin F; Chan EM; Yu M; Würstlin O; Kratz CP; Niemeyer CM; Flotho C; Hashino E; Chan RJ
    Mol Cell Biol; 2009 Aug; 29(16):4376-93. PubMed ID: 19528235
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Activating PTPN11 mutants promote hematopoietic progenitor cell-cycle progression and survival.
    Yang Z; Li Y; Yin F; Chan RJ
    Exp Hematol; 2008 Oct; 36(10):1285-96. PubMed ID: 18640765
    [TBL] [Abstract][Full Text] [Related]  

  • 3. c-Jun is a JNK-independent coactivator of the PU.1 transcription factor.
    Behre G; Whitmarsh AJ; Coghlan MP; Hoang T; Carpenter CL; Zhang DE; Davis RJ; Tenen DG
    J Biol Chem; 1999 Feb; 274(8):4939-46. PubMed ID: 9988737
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Non-lineage/stage-restricted effects of a gain-of-function mutation in tyrosine phosphatase Ptpn11 (Shp2) on malignant transformation of hematopoietic cells.
    Xu D; Liu X; Yu WM; Meyerson HJ; Guo C; Gerson SL; Qu CK
    J Exp Med; 2011 Sep; 208(10):1977-88. PubMed ID: 21930766
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genetic disruption of the PI3K regulatory subunits, p85α, p55α, and p50α, normalizes mutant PTPN11-induced hypersensitivity to GM-CSF.
    Goodwin CB; Yang Z; Yin F; Yu M; Chan RJ
    Haematologica; 2012 Jul; 97(7):1042-7. PubMed ID: 22315502
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Human somatic PTPN11 mutations induce hematopoietic-cell hypersensitivity to granulocyte-macrophage colony-stimulating factor.
    Chan RJ; Leedy MB; Munugalavadla V; Voorhorst CS; Li Y; Yu M; Kapur R
    Blood; 2005 May; 105(9):3737-42. PubMed ID: 15644411
    [TBL] [Abstract][Full Text] [Related]  

  • 7. M-CSF elevates c-Fos and phospho-C/EBPalpha(S21) via ERK whereas G-CSF stimulates SHP2 phosphorylation in marrow progenitors to contribute to myeloid lineage specification.
    Jack GD; Zhang L; Friedman AD
    Blood; 2009 Sep; 114(10):2172-80. PubMed ID: 19587381
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inflammatory response in hematopoietic stem and progenitor cells triggered by activating SHP2 mutations evokes blood defects.
    Solman M; Blokzijl-Franke S; Piques F; Yan C; Yang Q; Strullu M; Kamel SM; Ak P; Bakkers J; Langenau DM; Cavé H; den Hertog J
    Elife; 2022 May; 11():. PubMed ID: 35535491
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Potential clinical use of azacitidine and MEK inhibitor combination therapy in PTPN11-mutated juvenile myelomonocytic leukemia.
    Pasupuleti SK; Chao K; Ramdas B; Kanumuri R; Palam LR; Liu S; Wan J; Annesley C; Loh ML; Stieglitz E; Burke MJ; Kapur R
    Mol Ther; 2023 Apr; 31(4):986-1001. PubMed ID: 36739480
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Negative regulation of Stat3 by activating PTPN11 mutants contributes to the pathogenesis of Noonan syndrome and juvenile myelomonocytic leukemia.
    Zhang W; Chan RJ; Chen H; Yang Z; He Y; Zhang X; Luo Y; Yin F; Moh A; Miller LC; Payne RM; Zhang ZY; Fu XY; Shou W
    J Biol Chem; 2009 Aug; 284(33):22353-22363. PubMed ID: 19509418
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PI3K p110δ uniquely promotes gain-of-function Shp2-induced GM-CSF hypersensitivity in a model of JMML.
    Goodwin CB; Li XJ; Mali RS; Chan G; Kang M; Liu Z; Vanhaesebroeck B; Neel BG; Loh ML; Lannutti BJ; Kapur R; Chan RJ
    Blood; 2014 May; 123(18):2838-42. PubMed ID: 24553178
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Leukemogenic Ptpn11 causes fatal myeloproliferative disorder via cell-autonomous effects on multiple stages of hematopoiesis.
    Chan G; Kalaitzidis D; Usenko T; Kutok JL; Yang W; Mohi MG; Neel BG
    Blood; 2009 Apr; 113(18):4414-24. PubMed ID: 19179468
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Essential role of PTPN11 mutation in enhanced haematopoietic differentiation potential of induced pluripotent stem cells of juvenile myelomonocytic leukaemia.
    Shigemura T; Matsuda K; Kurata T; Sakashita K; Okuno Y; Muramatsu H; Yue F; Ebihara Y; Tsuji K; Sasaki K; Nakahata T; Nakazawa Y; Koike K
    Br J Haematol; 2019 Oct; 187(2):163-173. PubMed ID: 31222725
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Leukaemogenic effects of Ptpn11 activating mutations in the stem cell microenvironment.
    Dong L; Yu WM; Zheng H; Loh ML; Bunting ST; Pauly M; Huang G; Zhou M; Broxmeyer HE; Scadden DT; Qu CK
    Nature; 2016 Nov; 539(7628):304-308. PubMed ID: 27783593
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sunitinib selectively targets leukemogenic signaling of mutant SHP2 in juvenile myelomonocytic leukemia.
    He C; Peng Z; Zhang D; Guo Y; Liang T; Zhao Y; Yu L; Zhang Q; Chang Z; Xiao Y; Li N; Xue H; Wu S; Zhao ZJ; Zhang C; Chen Y
    Biochem Pharmacol; 2023 Jul; 213():115588. PubMed ID: 37187274
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Noonan syndrome-causing SHP2 mutants inhibit insulin-like growth factor 1 release via growth hormone-induced ERK hyperactivation, which contributes to short stature.
    De Rocca Serra-Nédélec A; Edouard T; Tréguer K; Tajan M; Araki T; Dance M; Mus M; Montagner A; Tauber M; Salles JP; Valet P; Neel BG; Raynal P; Yart A
    Proc Natl Acad Sci U S A; 2012 Mar; 109(11):4257-62. PubMed ID: 22371576
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro expansion of CD34(+)CD38(-) cells under stimulation with hematopoietic growth factors on AGM-S3 cells in juvenile myelomonocytic leukemia.
    Sakashita K; Kato I; Daifu T; Saida S; Hiramatsu H; Nishinaka Y; Ebihara Y; Ma F; Matsuda K; Saito S; Hirabayashi K; Kurata T; Uyen LT; Nakazawa Y; Tsuji K; Heike T; Nakahata T; Koike K
    Leukemia; 2015 Mar; 29(3):606-14. PubMed ID: 25102944
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Kit-Shp2-Kit signaling acts to maintain a functional hematopoietic stem and progenitor cell pool.
    Zhu HH; Ji K; Alderson N; He Z; Li S; Liu W; Zhang DE; Li L; Feng GS
    Blood; 2011 May; 117(20):5350-61. PubMed ID: 21450902
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Yolk sac erythromyeloid progenitors expressing gain of function PTPN11 have functional features of JMML but are not sufficient to cause disease in mice.
    Tarnawsky SP; Yoshimoto M; Deng L; Chan RJ; Yoder MC
    Dev Dyn; 2017 Dec; 246(12):1001-1014. PubMed ID: 28975680
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Functional evaluation of circulating hematopoietic progenitors in Noonan syndrome.
    Timeus F; Crescenzio N; Baldassarre G; Doria A; Vallero S; Foglia L; Pagliano S; Rossi C; Silengo MC; Ramenghi U; Fagioli F; Cordero di Montezemolo L; Ferrero GB
    Oncol Rep; 2013 Aug; 30(2):553-9. PubMed ID: 23756559
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.